Clinical trial · Observational
Clinicopathological Parameters of HER2 Low Breast Cancers
Exploring the Clinicopathological Parameters of HER2 Low Breast Cancers
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This was a retrospective cohort study which included all histologically proven cases of breast cancer in the 2 years from January 2022- December 2023 at a tertiary care centre. This study was performed in line with STROCSS criteria. The following clinicopathological data was retrieved from the histopathological records- age, tumor size, nodal involvement, lymphovascular/ perineural invasion, and Bloom Richardson grading. Routine histopathological processing was done followed by immunohistochemical analysis for ER, PR, HER2, Ki67 and AR. All the cases were categorised into Luminal A, B, Her2 enriched and triple-negative breast cancer based on the surrogate molecular classification. Further, all the cases were categorised into HER2 negative (no staining or incomplete weak membrane staining in ≤10% tumor cells), HER2 3+ (complete membranous staining) and HER2 low (1-2+ staining without amplification on ISH) based on consensus of two pathology consultants. The present study aims to evaluate the clinicopathological parameters of the HER2 low breast cancers.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| HER2 Low Breast Cancers | HER2-Low Breast Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| HER2 IHC | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- HER2 low
- interventionNames
- Diagnostic Test: HER2 IHC
- label
- HER2 negative
- interventionNames
- Diagnostic Test: HER2 IHC
Primary outcomes (6)
- measure
- Age (in years)
- timeFrame
- JANUARY 2022- DECEMBER 2023
- description
- It will be measured for HER2 low breast cancer patients
- measure
- Tumor stage (categorised from T1-T4)
- timeFrame
- JANUARY 2022- DECEMBER 2023
- description
Eligibility
Eligibility (as posted)
- Sex
- Female
Show eligibility criteria text
Inclusion Criteria: * All histologically proven cases of breast cancer in the 2 years from January 2022- December 2023 Exclusion Criteria: * Benign breast tumors
References
Publications (0)
Data not yet available